A Phase 2 interventional study of Ivermectin cream and vehicle control in Head Lice, sponsored by Topaz Pharmaceuticals Inc. Completed at 12 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2012-04-06.
Sponsored by Topaz Pharmaceuticals Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the safety and efficacy of a 0.5% ivermectin cream to a placebo in subjects infested with head lice when used in an "at home" environment.
Topaz Pharmaceuticals Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ivermectin cream
Drug: vehicle control
Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
Percentage of Participants With Treatment Success Following Treatment With Either Ivermectin or Placebo (Vehicle Control)
Treatment success was defined as the absence of live lice and was determined by visual examination of hair and scalp by a trained evaluator.
Time frame: Days 2 up to Day 15 post-treatment
Number of Participants Reporting Adverse Events Post-Treatment With Either Ivermectin or Placebo (Vehicle Control)
Time frame: Day 1 up to Day 28 post-application
Summary of the Reported Skin/Scalp Irritations Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Participants skin/scalp irritations were assessed before treatment (Day 1) and Post-treatment with either Ivermectin or placebo by a trained evaluator. Severe scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - Large areas of the scalp are red; Severe Excoriation: Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.
Time frame: Day 1 up to Day 15 post-application
Participants were enrolled and treated from 13 October 2009 to 02 December 2009 in 12 US clinical centers.
| Milestone | 0.5% Ivermectin | Placebo (Vehicle Control) |
|---|---|---|
| Started | 192 | 55 |
| Completed | 185 | 54 |
| Not completed | 7 | 1 |
| Withdrew: Lost to follow-up | 7 | 1 |
Treatment success was defined as the absence of live lice and was determined by visual examination of hair and scalp by a trained evaluator.
| Percent of Participants | 0.5% Ivermectin | Placebo (Vehicle Control) |
|---|---|---|
| Day 2 (N = 192, 55) | 95 | 53 (0 to 0) |
| Day 8 (N = 191, 55) | 83 | 49 (0 to 0) |
| Day 15 (N = 185, 54) | 76 | 35 (0 to 0) |
| Participants | 0.5% Ivermectin | Vehicle Control |
|---|---|---|
| Conjunctivitis | 1 | 0 (0 to 0) |
| Application site pruritus | 1 | 1 (0 to 0) |
| Influenza | 2 | 0 (0 to 0) |
| Nail bed infection | 1 | 0 (0 to 0) |
| Pharyngitis | 1 | 0 (0 to 0) |
| Pyoderma | 1 | 0 (0 to 0) |
| Swine influenza | 1 | 0 (0 to 0) |
| Upper respiratory tract infection | 5 | 0 (0 to 0) |
| Contusion | 1 | 0 (0 to 0) |
| Excoriation | 8 | 4 (0 to 0) |
| Scratch | 1 | 0 (0 to 0) |
| Headache | 1 | 0 (0 to 0) |
| Asthma | 1 | 0 |
| Dyspnoea | 1 | 0 |
| Oropharyngeal pain | 2 | 0 |
| Erythema | 2 | 1 |
| Pruritus | 4 | 0 |
| Rash maculo-papular | 1 | 0 |
Participants skin/scalp irritations were assessed before treatment (Day 1) and Post-treatment with either Ivermectin or placebo by a trained evaluator. Severe scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - Large areas of the scalp are red; Severe Excoriation: Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.
| Participants | 0.5% Ivermectin | Vehicle Control |
|---|---|---|
| Any Erythema Day 1 (Pre-treatment; N = 192, 55) | 26 | 5 (0 to 0) |
| Severe Erythema Day 1 (Pre-treatment; N = 192, 55) | 0 | 0 (0 to 0) |
| Any Erythema Day 2 (N = 192, 55) | 18 | 3 (0 to 0) |
| Severe Erythema Day 2 (N = 192, 55) | 0 | 0 (0 to 0) |
| Any Erythema Day 8 (N = 181, 29) | 7 | 0 (0 to 0) |
| Severe Erythema Day 8 (N = 181, 29) | 0 | 0 (0 to 0) |
| Any Erythema Day 15 (N = 152, 26) | 3 | 0 (0 to 0) |
| Severe Erythema Day 15 (N = 152, 26) | 0 | 0 (0 to 0) |
| Any Excoriation Day 1 (Pre-treatment; N = 192, 55) | 31 | 7 (0 to 0) |
| Severe Excoriation Day 1 (Pre-treatment; N=192, 55 | 0 | 0 (0 to 0) |
| Any Excoriation Day 2 (N = 192, 55) | 27 | 7 (0 to 0) |
| Severe Excoriation Day 2 (N = 192, 55) | 0 | 0 (0 to 0) |
| Any Excoriation Day 8 (N = 181, 29) | 15 | 2 (0 to 0) |
| Severe Excoriation Day 8 (N = 181, 29) | 0 | 0 (0 to 0) |
| Any Excoriation Day 15 (N = 152, 26) | 4 | 0 (0 to 0) |
| Severe Excoriation Day 15 (N = 152, 26) | 0 | 0 (0 to 0) |
| Any Pruritus Day 1 (Pre-treatment; N = 192, 55) | 134 | 36 (0 to 0) |
| Severe Pruritus Day 1 (Pre-treatment; N = 192, 55) | 17 | 3 (0 to 0) |
| Any Pruritus Day 2 (N = 192, 55) | 56 | 25 (0 to 0) |
| Severe Pruritus Day 2 (N = 192, 55) | 0 | 0 (0 to 0) |
| Any Pruritus Day 8 (N = 181, 29) | 32 | 5 (0 to 0) |
| Severe Pruritus Day 8 (N = 181, 29) | 0 | 0 (0 to 0) |
| Any Pruritus Day 15 (N = 152, 26) | 8 | 2 (0 to 0) |
| Severe Pruritus Day 15 (N = 152, 26) | 0 | 0 (0 to 0) |
| Any Pyoderma Day 1 (Pre-treatment, N = 192, 55) | 1 | 1 (0 to 0) |
| Severe Pyoderma Day 1 (Pre-treatment; N = 192, 55) | 0 | 0 (0 to 0) |
| Any Pyoderma Day 2 (N = 192, 55) | 1 | 1 (0 to 0) |
| Severe Pyoderma Day 2 (N = 192, 55) | 0 | 0 (0 to 0) |
| Any Pyoderma Day 8 (N = 181, 29) | 1 | 0 (0 to 0) |
| Severe Pyoderma Day 8 (N = 181, 29) | 0 | 0 (0 to 0) |
| Any Pyoderma Day 15 (N = 152, 26) | 0 | 0 (0 to 0) |
| Severe Pyoderma Day 15 (N = 152, 26) | 0 | 0 (0 to 0) |
Collected over Adverse event data were collected form Day 1 up to Day 28 post-treatment with either Ivermectin or Placebo. Non-serious events are listed at a 5.00% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5% Ivermectin | — | 0/192 (0%) | 8/192 (4.2%) |
| Placebo (Vehicle Control) | — | 0/55 (0%) | 4/55 (7.3%) |
| Event | 0.5% Ivermectin | Placebo (Vehicle Control) |
|---|---|---|
| ExcoriationInjury, poisoning and procedural complications | 8/192 | 4/55 |
| Age, Categorical(Participants) | 0.5% Ivermectin | Placebo (Vehicle Control) | Total |
|---|---|---|---|
| <=18 years | 147 | 35 | 182 |
| Between 18 and 65 years | 45 | 20 | 65 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(Years) | 0.5% Ivermectin | Placebo (Vehicle Control) | Total |
|---|---|---|---|
| Mean | 15.9 ± 12.9 | 19.6 ± 14.4 | 16.76 ± 13.32 |
| Sex: Female, Male(Participants) | 0.5% Ivermectin | Placebo (Vehicle Control) | Total |
|---|---|---|---|
| Female | 161 | 42 | 203 |
| Male | 31 | 13 | 44 |
| Region of Enrollment(Participants) | 0.5% Ivermectin | Placebo (Vehicle Control) | Total |
|---|---|---|---|
| United States | 192 | 55 | 247 |
The record gives a start of Oct 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 2 years 4 months after primary completion. A results delay was requested in Mar 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin
Topaz Pharmaceuticals Inc